Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven ...

The US Food and Drug Administration (FDA) has approved Gilead Sciences (Nasdaq: GILD) Yeztugo (lenacapavir) - the company’s ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

The US Food and Drug Administration has approved US biotech Incyte’s (Nasdaq: INCY) Monjuvi (tafasitamab-cxix) with ...

Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership ...

Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...

US biotech Actio Biosciences has raised $66 million in a series B round to support its pipeline of genetically targeted ...

The biopharmaceutical industry is grappling with a complex mid-year outlook in 2025, as accelerating innovation collides with ...

This office will serve as Celltrion’s central hub for UK operations and places the firm among a growing list of life sciences companies including Regeneron, Amgen, Gilead Sciences and Daiichi Sankyo ...

Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share.

US biopharma Mineralys Therapeutics has announced positive topline data from its Phase II Explore-CKD trial evaluating the ...

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...